Company profile
TREVI THERAPEUTICS, INC.
NASDAQ:TRVIBiotechnology: Pharmaceutical Preparations
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07487740 | phase1 | completed | 2026-02-27 | 2026-05-11 | Trevi Therapeutics | A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants |
| NCT04030026 | phase2 | completed | 2019-10-29 | 2022-05-27 | Trevi Therapeutics | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough |
| NCT07015398 | phase1 | completed | 2025-06-30 | 2025-09-12 | Trevi Therapeutics | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants |
| NCT05964335 | phase2 | completed | 2024-02-06 | 2025-04-24 | Trevi Therapeutics | Cough Reduction in IPF With Nalbuphine ER |
| NCT07868419 | phase3 | recruiting | 2026-09-30 | 2027-08-01 | Trevi Therapeutics | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets |
FDA applications (0)
No records yet.